A5006768444- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- BRCA gene mutations in cancer
- Diverticular Disease and Complications
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Genomics and Rare Diseases
- PARP inhibition in cancer therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Eosinophilic Esophagitis
- Epigenetics and DNA Methylation
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Cancer therapeutics and mechanisms
- Helicobacter pylori-related gastroenterology studies
Ospedale Policlinico San Martino
2014-2025
GTx (United States)
2024
University of Genoa
2004-2024
IRCCS Humanitas Research Hospital
2024
Humanitas University
2024
Azienda Ospedaliera S.Maria
2017-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2020
Alleanza Contro il Cancro
1987-2015
Piedmont Reference Center for Epidemiology and Cancer Prevention
2011-2014
Istituto per lo Studio e la Prevenzione Oncologica
1993-2011
A single flexible sigmoidoscopy at around the age of 60 years has been proposed as an effective strategy for colorectal cancer (CRC) screening.We conducted a randomized controlled trial to evaluate effect screening on CRC incidence and mortality. questionnaire assess eligibility interest in was mailed 236,568 men women, aged 55-64 years, who were randomly selected from six centers Italy. Of 56,532 respondents, interested eligible subjects assigned intervention group (invitation...
Background: A single sigmoidoscopy examination at around age 60 years has been proposed as a cost-effective strategy to prevent colorectal cancer. multicenter randomized controlled trial, the SCORE is in progress Italy estimate impact of this on cancer incidence and mortality duration protective effect. We present baseline screening outcomes. Methods: questionnaire was mailed random sample 236 568 people aged 55–64 assess their eligibility for interest screening. Those reporting history...
Abstract Purpose: GEP-NENs are rare malignancies with increasing incidence. Their molecular characteristics still undefined. We explored the underlying biology of and differences between gastrointestinal (GI) pancreatic (PNEN), high-grade (HG), low-grade (LG) tumors. Experimental Design: were analyzed using next-generation sequencing (NGS; MiSeq on 47 genes, NextSeq 592 genes), IHC, in situ hybridization. Tumor mutational burden (TMB) was calculated basis somatic nonsynonymous missense...
<h3>Background</h3> Most familial pancreatic cancer (FPC) remains unexplained. The identification of individuals with a high genetic risk developing adenocarcinoma (PC) is important to elucidate its biological basis and critical better define emerging strategies for the detection early neoplasms. <h3>Patients methods</h3> A series 225 consecutively enrolled patients PC were tested <i>CDKN2A</i> mutations. After personal family histories all had been reviewed, subset classified as FPC also...
Recent reports showed that the protective effect of flexible sigmoidoscopy (FS) screening was maintained up to17 years, although differences were reported by sex.To assess long-term reduction colorectal cancer (CRC) incidence and mortality after a single FS screening.Parallel randomized controlled trial. (ISRCTN registry number: 27814061).6 centers in Italy.Persons aged 55 to 64 years expressing interest having if invited, recruited from 1995 1999 followed until 2012 (incidence) 2014 2016...
The authors investigated the relationship between flow cytometric DNA index (DI, defined as ratio of content malignant cells to that normal cells) and other prognostic factors (grade stage, anatomical site, age sex) with survival 115 patients colorectal cancer. Multiple biopsy specimens from 62 were taken during colonoscopy before surgery. Additional samples 53 obtained paraffin-embedded material. All treated surgery only. Fresh–frozen material gave higher incidence aneuploidy than (79%...
This Viewpoint questions a recently published treatment algorithm for patients with HER2-amplified metastatic colorectal cancer and proposes alternative timing HER2 testing HER2-directed therapies.
The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet be determined. Multigene panel testing could increase diagnostic yield and better define the role genes. We characterized 273 CDKN2A/ARF CDK4-negative probands through a custom-designed targeted gene that included CDKN2A/ARF, CDK4, ACD, BAP1, MITF, POT1, TERF2IP, ATM, PALB2. Co-segregation, loss heterozygosity (LOH)/protein expression analysis, splicing characterization were...
Mismatch repair (MMR) testing on all new cases of colorectal cancer (CRC) has customarily been preferably performed surgical specimens, as more tissue is available; however, clinical trials for the use immune checkpoint inhibitors in neoadjuvant setting require MMR biopsy samples. This study aims at identifying advantages, disadvantages and any potential pitfalls evaluation how to cope with them. The prospective-retrospective, recruiting 141 biopsies (86 proficient (p)MMR 55 deficient...
The Lynch syndrome (LS) screening algorithm requires BRAF testing as a fundamental step to distinguish sporadic from LS-associated colorectal carcinomas (CRC). by immunohistochemistry (IHC) has shown variable results in the literature. Our aim was analyse concordance between
Abstract DNA ploidy of 64 colorectal adenomas and 49 adenocarcinomas, examined endoscopically, was studied by flow cytometry. We found aneuploidy in none the 105 normal mucosa samples (0%), 20 (31%), 36 adenocarcinomas (74%). correlated with size ( P = 0.02) degree dysplasia < 0.01) but not histologic type. Adenomas had a 45% incidence aneuploid stem lines index range 0.80–1.20, compared 8% case adenocarcinomas. The distribution values approximately normal, mean value 1.63 × 0.28. for...
TPS4124 Background: Moving stage III Colon Cancer (CC) into the precision medicine space is a priority in view of lack molecular markers driving adjuvant treatment. Retrospective studies have demonstrated tremendous prognostic impact circulating tumor DNA (ctDNA) analysis after curative intent surgery, and suggested that conversion ctDNA from detectable to undetectable chemotherapy reflects treatment failure. With these premises, we designed PEGASUS trial (NCT04259944). Methods: prospective...